Glycomic-Based Biomarkers for Ovarian Cancer: Advances and Challenges

• Main Authors: Francis Mugeni Wanyama, Véronique Blanchard
• Format: Article
• Language: English
• Published: MDPI AG 2021-04-01
• Series: Diagnostics
• Subjects: ovarian cancer; biomarker; clinical biomarker; glycan
• Online Access: https://www.mdpi.com/2075-4418/11/4/643

Ovarian cancer remains one of the most common causes of death among gynecological malignancies afflicting women worldwide. Among the gynecological cancers, cervical and endometrial cancers confer the greatest burden to the developing and the developed world, respectively; however, the overall survival rates for patients with ovarian cancer are worse than the two aforementioned. The majority of patients with ovarian cancer are diagnosed at an advanced stage when cancer has metastasized to different body sites and the cure rates, including the five-year survival, are significantly diminished. The delay in diagnosis is due to the absence of or unspecific symptoms at the initial stages of cancer as well as a lack of effective screening and diagnostic biomarkers that can detect cancer at the early stages. This, therefore, provides an imperative to prospect for new biomarkers that will provide early diagnostic strategies allowing timely mitigative interventions. Glycosylation is a protein post-translational modification that is modified in cancer patients. In the current review, we document the state-of-the-art of blood-based glycomic biomarkers for early diagnosis of ovarian cancer and the technologies currently used in this endeavor.